Loading company financials…
NEW YORK STOCK EXCHANGE, INC. · Health Care · CIK 0001739940
$304.37
-0.73% · delayed ~15 min
Last price from Oct 21, 2026
$80.19B market value
From Cigna Group's FY2025 10-K, filed Feb 26, 2026 · read the filing
Cigna sells insurance. It took in $274.90B last year, which makes it one of the largest companies in the world. Of every dollar it sells, about 2 cents is left as profit.
The financial picture is mixed, with profitability, growth and debt needing attention.
A conclusion from the filings, not a recommendation. Detailed figures and supporting evidence appear in their dedicated sections below.
Financial health
A mixed picture — some clear strengths and some weaknesses.
From Cigna Group's FY2025 annual filing · share price scored separately
Largest year-over-year changes in FY2025
Profit
$3.43B → $5.96B
Earnings per share
$12.54 → $22.61
Gross margin
26.1% → 21.8%
Revenue
$247.12B → $274.90B
Measured against FY2024, from the 10-K filed Feb 26, 2026
Improved: +73.5%
$3.43B to $5.96BCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
How the latest move compares (quote delayed ~15 min), and what was published around it
CI fell 0.73% on the latest quote. The average Financials company tracked here moved +1.07%, and the S&P 500 −1.04%. That is 1.8 points below its sector and in line with the market.
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
Opinions from 35 analysts covering this company, as of . Their views, not this site's.
Of 35 analysts publishing on this company, 9 say strong buy, 17 say buy and 9 say hold. Analysts are paid to publish a view and are wrong often; the split above says how much they agree with each other, which is the part a single headline rating hides.
Published by Finnhub. Analyst coverage skews towards larger companies and towards optimism — sell ratings are rare across the whole market, so a company with none is ordinary rather than endorsed.
The essentials
Each answered from the filings, with the numbers behind it.
Yes. It keeps about 2 cents of every dollar of sales as profit, earning $5.96B last year.
Slowly. Sales grew 11.2% last year.
For every $1 it owes, it owns $1.36 in assets. Banks and insurers always carry high debt — that is how lending works — so this is normal for the industry and not comparable with other sectors.
Core operating and valuation reference metrics
Whether the dividend is covered by what the business actually earns
It pays out 27 cents of every dollar of profit and keeps the rest, which leaves the payment comfortably covered. It paid out 17% of the cash its operations generated. It has paid in each of the last 7 years.
GoodNext payment expected around , projected from how regularly it has paid before rather than from a date the company has announced.
Figures from the FY2025 annual filing
Last year it earned $5.96B and generated $9.60B of cash from operations.
As reported to the SEC, in USD. Hover or show sources to see where each figure came from.
| Income statement | FY202510-K · Feb 26, 2026Filing for FY2025 | FY202410-K · Feb 26, 2026Filing for FY2024 | FY202310-K · Feb 26, 2026Filing for FY2023 | FY202210-K · Feb 29, 2024Filing for FY2022 | FY202110-K · Feb 29, 2024Filing for FY2021 | ChangeFY2025 vs FY2024 |
|---|---|---|---|---|---|---|
| RevenueWhat is this? | $274.90B | $247.12B | $195.26B | $180.52B | $174.07B | +11.2% |
| Cost of revenue | $214.99B | $182.51B | $133.80B | $124.83B | $117.55B | +17.8% |
| Gross profit | $59.91B† | $64.61B† | $61.46B† | $55.68B† | $56.52B† | −7.3% |
| Gross marginGross profit ÷ revenueWhat is this? | 21.8% | 26.1% | 31.5% | 30.8% | 32.5% | −4.4 pts |
| Selling, general and administrative | $14.62B | $14.84B | $14.82B | $13.17B | $13.01B | −1.5% |
| Operating income | $9.20B | $9.42B | $8.54B | $8.45B | $7.94B | −2.3% |
| Operating marginOperating income ÷ revenueWhat is this? | 3.3% | 3.8% | 4.4% | 4.7% | 4.6% | −0.5 pts |
| Interest expense | $1.40B | $1.50B | $1.40B | $1.30B | $1.30B | −6.7% |
| Income before tax | $7.78B | $5.27B | $5.51B | $8.40B | $6.79B | +47.7% |
| Net income | $5.96B | $3.43B | $5.16B | $6.78B | $5.42B | +73.5% |
| Net marginNet income ÷ revenueWhat is this? | 2.2% | 1.4% | 2.6% | 3.8% | 3.1% | +0.8 pts |
| Earnings per shareNet income ÷ shares outstanding at the period end — close to, but not the same as, the reported EPSWhat is this? | $22.61 | $12.54 | $17.65 | $22.71 | $16.78 | +80.3% |
† calculated from other reported figures, such as total liabilities as assets minus equity.
This company's latest filing beside its peers' stored scores
| Company | Health | F-Score | Revenue growth | Profit margin | P/E | Debt to equity |
|---|---|---|---|---|---|---|
| CICigna Group · this page | 6.0/10 | 7/9 | 11.2% |
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Officers, directors and major shareholders must report within two business days of a trade.
Sold on the open market — 617 shares at $284.05 ($175.3K)
Holds 5,053 shares after this filing.
Was granted or awarded shares — 3,113 shares
Holds 41,030 shares after this filing.
20 recent filings, newest first. Each is labelled from its form and item numbers, not from its wording.
Had a director or senior officer leave or join
Read the filingMade a Regulation FD disclosure
Read the filingWrite down why you are following Cigna Group, what has to go right and what would change your mind, then see each new annual report measured against it. Sign in to start one.
Go deeper
Every figure above traces back to a filing in the timeline, each linked to the document itself.
Coverage from the last 30 days
What Does Progyny's Falling Multiple Really Say?
Yahoo ·
Molina (MOH) Surpasses Q3 Earnings and Revenue Estimates
Yahoo ·
What Could Stop CVS Health Stock Over The Next Six Months?
Yahoo ·
9 Health Care Stocks Whale Activity In Today’s Session
Benzinga ·
How CVS' Aetna Is Advancing Efforts to Reduce Administrative Burden
Yahoo ·
Every company's figures are checked for internal consistency: the balance sheet adding up, figures sharing one currency, cash flow and share counts within plausible ranges, and how recent the latest annual report is. Nothing here changes a figure.
Financial figures are from CI's 10-K for fiscal year 2025 (period ending 2025-12-31, filed Feb 26, 2026), reported under the US GAAP taxonomy. View the source filing.
3 of 4 scored areas had enough reported figures to judge
The score averages profitability, growth, debt and accounting. Accounting had too few reported figures and is left out of the average rather than counted as a weakness, so a company is never marked down for a figure it did not publish. Cash generation is shown for context and already feeds profitability. Valuation is scored separately, because a share price says nothing about whether the business is sound. 9 of the 9 Piotroski checks could be evaluated. How the score works
Each year scored only from its annual report as it was first filed
| Fiscal year | Health | F-Score | Scored from |
|---|---|---|---|
| FY2025 | 6.0 | 7/9 | 10-K, filed Feb 26, 2026 |
| FY2024 | 7.3 | 6/9 | 10-K, filed Feb 27, 2025 |
| FY2023 | 6.0 | 8/9 | 10-K, filed Feb 29, 2024 |
| FY2022 | 6.0 | 7/9 | 10-K, filed Feb 29, 2024 |
| FY2021 | 6.0 | 6/9 | 10-K, filed Feb 24, 2022 |
| FY2020 | 6.0 | 8/9 | 10-K, filed Feb 25, 2021 |
A later restatement never reaches back into an earlier year, and every year is scored without a share price, so the latest point can differ a little from the headline score, which uses today's price.
Every check behind the three models, and what each one tests
7 of 9 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's.
not reported — Not meaningful for banks, insurers and other financial companies. Their balance sheets have no working capital and are leveraged by design, which this model misreads as distress.
Not meaningful for banks, insurers and other financial companies. Their balance sheets have no working capital and are leveraged by design, which this model misreads as distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
not reported — Not meaningful for banks, insurers and other financial companies. Their balance sheets have no working capital and are leveraged by design, which this model misreads as distress.
Not meaningful for banks, insurers and other financial companies. Their balance sheets have no working capital and are leveraged by design, which this model misreads as distress.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
Improved: +80.3%
$12.54 to $22.61Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Deteriorated: −4.3 pts
26.1% to 21.8%Significant
Why it matters: What survives each sale before overheads. Falling gross margin usually means the company is discounting or its input costs rose — it is the earliest place pricing pressure shows.
Improved: +11.2%
$247.12B to $274.90BNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Deteriorated: -7.3%
$64.61B to $59.91BNotable
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Deteriorated: +6.7%
$28.94B to $30.87BNotable
Why it matters: Rising debt is not automatically bad — borrowing to build something that earns more than the interest is ordinary. It matters when it grows faster than the profit meant to service it.
Improved: -3.8%
273.8M to 263.5MNotable
Why it matters: The company bought back stock, so each remaining holding owns slightly more of it. Worth checking it was not funded by borrowing.
Q2 FY2026 against Q2 FY2025, from the 10-Q filed Jul 30, 2026 — read it.
Improved: +45.5%
$4.33B to $6.30BCritical
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Improved: +16.0%
$2.31B to $2.68BSignificant
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Improved: +6.7%
$67.18B to $71.67BNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Improved: +7.6%
$13.91B to $14.96BNotable
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Improved: +8.4%
$1.53B to $1.66BNotable
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Improved: +10.1%
$5.71 to $6.29Notable
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Deteriorated: +9.8%
$26.48B to $29.09BNotable
Why it matters: Rising debt is not automatically bad — borrowing to build something that earns more than the interest is ordinary. It matters when it grows faster than the profit meant to service it.
Improved: -1.6%
268.2M to 264.0MNotable
Why it matters: The company bought back stock, so each remaining holding owns slightly more of it. Worth checking it was not funded by borrowing.
Q2 FY2026 against Q1 FY2026, from the 10-Q filed Jul 30, 2026 — read it. Quarter-to-quarter moves include seasonal swings — a retailer's holiday quarter — which the year-earlier comparison removes.
Improved: +13.5%
$2.36B to $2.68BNotable
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Deteriorated: -10.5%
$7.04B to $6.30BNotable
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
5 other measures barely moved. Figures compare the two most recent annual filings — read the latest one. Moves are graded on fixed lines — 5%, 15% and 40% for amounts, and 1, 3 and 8 points for margins — as notable, significant or critical. Nothing here reads the management commentary, which is where a company explains its own numbers.
These coincide with the move in time. None is presented as its cause: a price can move on news that names no company, on the wider market, or on trading that no document records.
Filter by minute, hour, day or week — or compare against peers
Loading price history…
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 2.6% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
The trailing P/E is 11.8x — investors pay $11.8 for each $1 of trailing profit.
Not meaningful for banks, insurers and other financial companies. Their balance sheets have no working capital and are leveraged by design, which this model misreads as distress.
Reported annual figures
| 2.2% |
| 13.46x |
| 2.78x |
| CVSCVS HEALTH Corp | 4.7/10 | 8/9 | 7.8% | 0.4% | 67.92x | 2.37x |
|---|
| DGXQUEST DIAGNOSTICS INC | 8.0/10 | 8/9 | 11.8% | 9.0% | 27.22x | 1.26x |
|---|
| LHLABCORP HOLDINGS INC. | 7.0/10 | 8/9 | 7.2% | 6.3% | 30.94x | 1.13x |
|---|
| DVADAVITA INC. | 4.7/10 | 6/8 | 6.5% | 5.5% | 17.08x | -25.07x |
|---|
| Median of peers | 5.8/10 | — | 7.5% | 5.9% | 29.08x | 1.20x |
|---|
Peers come from the company's industry classification. A difference describes the companies; it does not rank them.
Sold on the open market — 2,677 shares at $279.61 ($748.5K)
Holds 25,880 shares after this filing.
Exercised stock options — 14,045 shares at $192.02 ($2.7M)
Holds 46,692 shares after this filing.
Sold on the open market — 19,436 shares at $276.27 ($5.4M)
Holds 27,256 shares after this filing.
Exercised stock options — 1,301 shares at $192.02 ($249.8K)
Holds 28,557 shares after this filing.
Notice filed ahead of a planned sale — the sale itself has not necessarily happened yet.
Filed notice to sell 617 shares ($175.3K) on or after .
Shares originally obtained via Restricted Stock Vesting.
Filed notice to sell 2,677 shares ($748.4K) on or after .
Shares originally obtained via Stock Option Exercise.
Filed notice to sell 19,436 shares ($5.4M) on or after .
Shares originally obtained via Restricted Stock Vesting.
Estimated from how often this has happened before, not a confirmed date.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Quarterly report for Q2 FY2026
Revenue +6.7% · Cash +45.5% · Operating income +16.0% — against Q2 FY2025
Published results
Read the filingMade a Regulation FD disclosure
Read the filingQuarterly report for Q1 FY2026
Gross profit -15.8% · Operating income +19.6% · Profit +25.0% — against Q1 FY2025
Read the filingPublished results
Read the filingHeld a shareholder vote
Read the filingProxy statement for a shareholder meeting
Read the filingHad a director or senior officer leave or join · Made a Regulation FD disclosure
Read the filingMade a Regulation FD disclosure
Read the filingAnnual report for FY2025
Revenue +11.2% · Profit +73.5% · Earnings per share +80.3% — against FY2024
Read the filingPublished results
Read the filingReported another event
Read the filingQuarterly report for Q3 FY2025
Revenue +9.5% · Profit margin +1.5 pts · Profit +139.2% — against Q3 FY2024
Read the filingPublished results
Read the filingHad a director or senior officer leave or join
Read the filingSigned a material agreement · Took on a direct financial obligation · Reported another event
Read the filingMade a Regulation FD disclosure
Read the filingQuarterly report for Q2 FY2025
Revenue +11.0% · Gross margin −5.8 pts · Cash -36.2% — against Q2 FY2024
Read the filingPrimary sources and further research